

 Indications for Use of PCV13 and Schedule Routine Schedule 4 doses: a 3-dose primary series at 2, 4, 6 months and a booster dose at 12-15 months Children who do not start or continue the series on time may need less doses to complete the series Children with an incomplete schedule who are: Healthy & ages 24 through 59 months receive 1 	 Vaccine Administration Intramuscular (IM) injection in the anterolateral thigh or deltoid of the arm 1 inch needle, 22-25 gauge needle Professional judgment is appropriate when selecting needle length Can be given with other vaccines, at the same visit (use separate sites; space at least 1 inch a part)
 dose High risk & ages 2 through 18 years receive 1-2 doses based on previous history (see below) <u>Minimal Interval</u>: 4 weeks between doses given <u>before</u> age 12 months 8 weeks between doses given <u>at/after</u> age 12 months 	 Storage and Handling Store in the refrigerator between 35°-46° F (2°-8°C) Do NOT freeze Keep in the original box

CONTRAINDICATIONS

• An anaphylactic reaction to a prior dose of Pneumococcal Conjugate Vaccine (PCV7 or PCV13) or any diphtheriatoxoid containing vaccine **or** an anaphylactic reaction to a component of PCV13 vaccine

PRECAUTIONS

• Moderate or acute severe illness

TRANSITIONING TO PCV13 FROM PCV7¹

• Children through age 59 months that have completed a PCV7 series and have not received a dose of PCV13: -Give one dose of PCV13

-Minimum interval of 8 weeks since the last dose of any pneumococcal vaccine (PCV13 or PPSV23)

High Risk Children

-Ages 24 through 71 months²

- If incomplete schedule of 2 or less doses, give 2 doses of PCV13
- If incomplete schedule of 3 doses, give 1 dose of PCV13
- Use a minimum interval of 8 weeks since the last dose of PCV7, PCV13, or PPSV23

-Ages 6 through 18 years³

- Give a single supplemental dose of PCV13 if no previous dose of PCV13, regardless of previous history of receiving PCV7 or PPSV23 vaccine
- Use a minimum interval of 8 weeks since the last dose of PCV7 or PPSV23

Further Points

- PCV Vaccine Information Statement (VIS), can be found at <u>http://www.immunize.org/vis/</u>
- PCV13 contains an additional serotypes against *Streptococcus pneumoniae*, including 19a, the most common pneumococcal serotype and often reistant to antibiotics.
- PCV13= Pneumococcal Conjugate Vaccine, Prevnar™
- PPSV23= Pneumococcal Polysaccharide Vaccine, Pneumovax®

¹Refer to "Recommended Schedule for Administering Doses of PCV13" for more details (www.immunize.org/catg.d/p2016.pdf)

²High Risk children ages 24-71 months include: a) Immunocompetent (chronic lung or heart disease, diabetes, cochlear implant, cerebrospinal fluid (CSF) leak, b) immunocompromised (HIV, chronic renal or nephrotic syndrome, chemotherapy or radiation therapy for neoplasms, leukemia, lymphoma, solid organ transplant), c) functional or anatomic asplenia (no spleen, sickle cell disease)

³High risk children ages 6-18 years include: functional or anatomic asplenia, including sickle cell disease, HIV infection or other immunocompromising condition, cochlear implant or CSF leak

Refer to "Prevention of Pneumococcal Disease among Infants & Children, Use of PCV13 & PPSV23" MMWR December 10, 2010", ACIP VFC "Vaccines to Prevent Pneumococcal Disease" February 2013 at <u>www.cdc.gov/vaccines</u>.